TG Therapeutics Inc (TGTX)

Return on equity (ROE)

		Dec 31, 2024	Sep 30, 2024	Jun 30, 2024	Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020
Net income (ttm)	US$ in thousands	23,383	-14,364	95,686	41,197	12,672	-25,906	-175,654	-168,554	-198,335	-238,679	-288,498	-326,485	-348,100	-342,980	-344,506	-318,893	-279,381	-230,734	-205,501	-188,830
Total stockholders’ equity	US$ in thousands	222,364	192,157	177,568	160,109	160,502	164,769	40,453	27,433	58,587	100,481	129,035	170,386	237,153	311,517	383,130	445,285	519,350	170,658	194,227	-1,353
ROE		10.52%	-7.48%	53.89%	25.73%	7.90%	-15.72%	-434.22%	-614.42%	-338.53%	-237.54%	-223.58%	-191.61%	-146.78%	-110.10%	-89.92%	-71.62%	-53.79%	-135.20%	-105.80%	—

December 31, 2024 calculation

ROE = Net income (ttm) ÷ Total stockholders’ equity
= $23,383K ÷ $222,364K
= 10.52%

TG Therapeutics Inc experienced a sharp decline in its return on equity (ROE) from March 31, 2020, to June 30, 2022, with negative ROE figures worsening over this period. The negative ROE indicates that the company was generating losses that exceeded shareholder equity during this time frame.

However, there was a notable turnaround starting from December 31, 2023, where the ROE shifted to positive territory, indicating the company began generating profits relative to its equity. This positive trend continued through June 30, 2024, with ROE reaching significant levels like 53.89% on that date.

Overall, the company's ROE has shown significant volatility and fluctuations, transitioning from deep negative values to positive returns in recent periods. Shareholders may find the recent positive ROE figures encouraging, suggesting improved profitability and efficiency in the utilization of equity.